OHIP
July 1991 Fee for service and shadow-billing claims for diagnostic, laboratory, and surgical services, information on associated diagnoses for laboratory tests and surgical services, as well as the date of the services and physician identifiers. RPDB April 1990 Basic demographic information including age, sex, date of death and date last eligible for Ontario health card.
ODB April 1990
Drug claims information for drugs covered by the Ministry of Health and Long Term Care. Contains prescription, pharmacy and prescribing physician information for all drug claims and drug services paid for by the Ministry of Health and Long Term Care of Ontario (patients 65 years of age and older, patients on special drug access and assistance programs, and patients participating in pharmacist medication reconciliations). ODD April 1991 ICES derived disease specific database that identifies all incident and prevalent diabetic patients within the province of Ontario.
HYPER
April 1991 ICES derived disease specific database that identifies all incident and prevalent hypertensive patients within the province of Ontario.
CHF
April 1991 ICES derived disease specific database that identifies all incident and prevalent congestive heart failure patients within the province of Ontario. 12 Diagnosis date in Ontario COPD Database that precedes index date 
COPD

Anticoagulants
All drugs from ODB with subclass name "HEPARINS", "VITAMIN K ANTAGONISTS", "ANTICOAGULANTS", "ANTICOAGULANTS MISCELLANEOUS", "SYNTHETIC ANTITHROMBOTIC AGENTS", "LOW MOLECULAR WEIGHT HEPARINS (LMWH)". Prednisone
All drugs from ODB with drug name "PREDNISONE"
Anti-diabetics All drugs from ODB with subclass name "ORAL ANTI-GLYCEMICS" Insulins All drugs from ODB with subclass name "INSULINS" Fluoroquinolone All drugs from ODB with subclass name "FLUOROQUINOLONES"
Primary outcomes
Death
Death from CIHI-DAD for inpatient death, and from RPDB for outpatient. IPTW=inverse probability of treatment weighted; HR=hazard ratio; MACE=major adverse cardiovascular events; CI=confidence interval.
Secondary outcomes
MACE
